Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CLPP | Q16740 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3534572 | 0.87 | SNCA (0.47) | SNCAAPPHIF1AIDO1ALDH1A1 | |
| Bromide SCHEMBL8015170 | 0.84 | SNCA (0.51) | SNCAAPPHIF1AHTTALDH1A1 | |
| Bromide SCHEMBL30721146 | 0.84 | SNCA (0.51) | SNCAAPPHIF1AHTTALDH1A1 | |
| Bromide SCHEMBL9351092 | 0.84 | HIF1A (0.42) | SNCAHIF1ASLC6A4PTPRBHCRTR2 | |
| Bromide SCHEMBL1508860 | 0.80 | SNCA (0.47) | SNCAAPPHIF1ASLC6A4HCRTR2 | |
| Bromide SCHEMBL6457063 | 0.79 | SNCA (0.49) | SNCAAPPHIF1AALDH1A1CYP3A4 | |
| Bromide SCHEMBL973293 | 0.78 | SNCA (0.49) | SNCAALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL25411424 | 0.77 | SNCA (0.47) | SNCAAPPHIF1ASLC6A4 | |
| Bromide SCHEMBL1508663 | 0.77 | SNCA (0.47) | SNCAAPPHIF1ASLC6A4CYP3A4 | |
| Bromide SCHEMBL31753766 | 0.76 | TRPV4 (0.45) | SNCASLC6A4KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846910-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-09-30 | — | — | US | disclosed |
| US-8816073-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2014-08-26 | — | — | US | disclosed |
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-14 | — | — | US | disclosed |
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2013-11-07 | — | — | US | disclosed |
| US-8557998-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2013-10-15 | — | — | US | disclosed |
| US-8507670-B2 | Matrix metalloproteinase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2013-08-13 | — | — | US | disclosed |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| EP-2074093-B1 | PROCESS FOR PREPARING MATRIX METALLOPROTEINASE INHIBITORS AND CHIRAL AUXILIARY THEREFOR | RANBAXY LAB LTD (IN) | 2012-10-10 | — | — | EP | disclosed |
| US-8232405-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| EP-2474531-A2 | Matrix metalloproteinase inhibitors | Ranbaxy Laboratories Limited (IN) | 2012-07-11 | — | — | EP | disclosed |
| US-8063223-B2 | Benzylpiperizine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2322507-A1 | Matrix metalloproteinase inhibitors | Ranbaxy Laboratories Limited (IN) | 2011-05-18 | — | — | EP | disclosed |
| EP-2239254-A1 | BENZYLPIPERIZINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20100113792-A1 | BENZYLPIPERIZINE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303786-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | SNCA 2844/4885APP 3450/4885HIF1A 1201/4885 |
| US-20130302378-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | SNCA 4420/4885APP 399/4885HIF1A 34/4885 |
| US-20100113792-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | SNCA 2844/4885APP 3450/4885HIF1A 1201/4885 |
| US-20120259122-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | SNCA 2844/4885APP 3450/4885HIF1A 1201/4885 |
| US-20130295141-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP25 | SNCA 4420/4885APP 399/4885HIF1A 34/4885 |
| US-20100081610-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP8, MMP12 | SNCA 4495/4885APP 341/4885HIF1A 48/4885 |
| US-20110118312-A1 | BENZYLPIPERIZINE COMPOUND | OPRM1, GRM1, CHRM1 | SNCA 2844/4885APP 3450/4885HIF1A 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.